The EPS projection of Bristol-Myers Squibb Company (NYSE:BMY) for quarter ended 2016-09-30 is $0.64. Last week, the projection for EPS was $0.64 against target of $0.64, a month earlier. While 2-months ago, this projection was $0.64 versus forecast of $0.64a quarter months earlier, posting a deviation of 0%.
Bristol-Myers Squibb Company (NYSE:BMY) posted that 18 days earlier, the share price was revised 1 times on upside. In addition, negative revisions were 1.
In last week, negative EPS revisions were 0 times and positive EPS revisions were 0 times. In last one-month and two month the positive revisions were 0 and 0. While in last 120 and 90 days, positive revisions were 5, and 4, correspondingly.
The per-share earnings downgrade for Bristol-Myers Squibb Company (NYSE:BMY) in the preceding 30 and 120 were 2 and 0. While in 60 and 90 days were 2, and 0, in that order.
Bristol-Myers Squibb Company (NYSE:BMY) EPS target was $0.64 for the quarter closed 1. It was based on 10 calls. As on 2016-04-28 the EPS was $0.74. The change was $0.08, posting a deviation of 12.12%. The price projections gave a standard deviation of 0.03.
Quarterly Sales Estimates
Bristol-Myers Squibb Company (NYSE:BMY) sales prediction for the fiscal 2016 stands at $4865.7 and the median estimate is at $4840.1. Almost 3 analysts gave sales target.
Among this, the highest sales estimate is $4962 while the lowest target is $4795 showing standard deviation of 86.393%.
As many as 3 analysts have positive sales targets revision while 3 reduced sales estimates, posting a deviation of 0%.
Last month, 3 experts have positive sales number revision. Also, 3 research groups lowered the sales projections, posting a deviation of 1.946%.
A quarter ago, 3 hiked sales target and 3 reduced sales forecast, posting a deviation of 5.215%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...